SerpinE1 _ PLANH1 _ PAI1 Antibody
- Known as:
- SerpinE1 _ PLANH1 _ PAI1 Antibody
- Catalog number:
- 10296-RP01
- Product Quantity:
- 200
- Category:
- -
- Supplier:
- Smart Serology
- Gene target:
- SerpinE1 _ PLANH1 PAI1 Antibody
Related genes to: SerpinE1 _ PLANH1 _ PAI1 Antibody
- Gene:
- SERPINE1 NIH gene
- Name:
- serpin family E member 1
- Previous symbol:
- PLANH1, PAI1
- Synonyms:
- PAI
- Chromosome:
- 7q22.1
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2019-04-23
Related products to: SerpinE1 _ PLANH1 _ PAI1 Antibody
Related articles to: SerpinE1 _ PLANH1 _ PAI1 Antibody
- IDH wild-type glioblastoma (IDH-wt GBM) exhibits substantial intratumoral heterogeneity, which contributes to treatment resistance, disease recurrence, and variable clinical outcomes. This study aimed to identify radiomics-based intratumoral heterogeneity (RITH) subtypes in IDH-wt GBM and to assess their prognostic relevance, associated pathomic differences, and transcriptomic associations. - Source: PubMed
Publication date: 2026/07/03
Duan XinNiu WenjuLi XuanLi ZehuiLiang QianYang XiangliTan YanZhang Hui - Maternal recognition of pregnancy (MRP) in the mare requires coordinated adaptations of both the conceptus and the endometrium during the peri-recognition interval; however, integrated transcriptomic analyses of both compartments within the same biological window remain limited. Here, we analyzed conceptus RNA-seq data across embryonic age (Days 8 and 12 post ovulation) and endometrial RNA-seq data across pregnancy status (pregnant versus non-pregnant mares sampled between Days 8 and 12 post ovulation). In pregnant mares, conceptus recovery and endometrial biopsy collection were performed within the same gestation, allowing biological integration of embryo and maternal transcriptomes while preserving tissue-specific statistical contrasts. - Source: PubMed
Publication date: 2026/06/18
Da Silva Álvarez EvaOrtiz-Rodríguez José MMartín-Cano Francisco EÁlvarez-Barrientos AlbertoBecerro-Rey LauraGil María CRedondo EloyMasot JavierAparicio Inés MPeña Fernando JOrtega-Ferrusola Cristina - Pulmonary fibrosis is a refractory and serious disease, and there is a need for developing effective clinical treatment strategies. A major cause of pulmonary fibrosis is excessive deposition of extracellular matrix, while the overexpression of plasminogen activator inhibitor 1 (PAI-1) is one of the key drivers of the excessive deposition. Here, we report a targeted DNA triplex-forming oligonucleotide (TFO) liposome (tLipo-TFO1) for pulmonary fibrosis gene therapy to accelerate the clearance of deposited extracellular matrix. tLipo-TFO1 can block the expression of the Serpine1 gene of pulmonary fibrotic cells and thereby downregulate the function of Serpine1-gene-encoded PAI-1 protein. Functional assessments show pulmonary fibrosis-targeting, fibrinolysis-activating effect, as well as significant efficacy in treating pulmonary-fibrosis-bearing mice in vivo. Our study thus suggests that this targeted DNA TFO liposome could be a gene therapy approach for pulmonary fibrosis. - Source: PubMed
Publication date: 2026/07/01
Xu JiaruiXie YingLuo QianRen YuxinWang JinlingQin ChichengLi PeishanLiu YixuanCheng YuntaoJiang MinChen YulingWei DingyiZhang HongruiLi JianweiLu Wanliang - This study evaluated circulating mRNAs (B2M, TIMP-1, CLU, SERPINE1, GAL3, and S100A9) as potential biomarkers for colorectal cancer (CRC). Plasma levels were measured in CRC patients (stages I-IV, = 178) and healthy individuals (HIs, = 171). B2M, TIMP-1, CLU, and S100A9 mRNA levels were significantly elevated in CRC patients vs. HIs. B2M differed only in stage IV, while TIMP-1, CLU, and S100A9 showed significance across all stages except I. A composite index, I-BTC, was developed using B2M, TIMP-1, and CLU via logistic regression. I-BTC improved discrimination between HIs and CRC patients, even at stage I ( = 0.001), with stronger significance in later stages ( ≤ 0.0001). These results validate analytical robustness of the method and highlight its diagnostic potential including for early-stage CRC through specific mRNAs combinations. - Source: PubMed
Publication date: 2026/06/17
Mazard ThibaultGrosgeorges MarieVeyrie LauraThezenas SimonPastor BricePisareva EkaterinaLossaint GéraldLopez-Crapez EvelyneYchou MarcThierry Alain RPrévostel CorinneBlache Philippe - Focal stroke leads to complex changes in the cerebral microcirculation in surviving brain tissues that strongly influence functional recovery. The gene Serpine1 and its protein product Plasminogen Activator-Inhibitor-1 (PAI-1), are highly upregulated in endothelial cells after stroke, are known to inhibit clot breakdown and are an established biomarker of cardiovascular disease in humans. Therefore, we hypothesized that inhibiting this pathway specifically within brain endothelial cells could be beneficial for stroke recovery by promoting fibrinolysis and cerebral blood flow (CBF). Using longitudinal in vivo imaging, we first show in wild-type mice that focal ischaemic stroke leads to a transient reduction in peri-infarct CBF at 6 h (~41%), which is then followed by hyperperfusion at 3 days (~29%). Contrary to expectation, viral knockdown of Serpine1 in brain endothelial cells led to a persistent reduction in peri-infarct capillary width (~20-37%) and red blood cell velocity (~36-50%) over this time. Consistent with this effect on CBF, topical application of PAI-1 increased capillary diameter and flow. Of note, lowered peri-infarct CBF in Serpine1 knockdown mice appeared to play a protective role in stroke recovery since it attenuated deleterious blood-brain barrier disruption and pro-inflammatory gene expression. In agreement with this, Serpine1 knockdown mice displayed enhanced recovery of sensory evoked cortical responses, as well as improved cognitive and sensorimotor function relative to wild-type mice. These findings suggest that endothelial Serpine1/PAI-1 signalling can influence vessel tone and highlight its therapeutic potential in promoting stroke recovery. Further, our data challenge the assumption that increased CBF after the hyper-acute phase of stroke is better for recovery and suggest that carefully tuning flow, rather than maximizing it, may be an optimal strategy. - Source: PubMed
Publication date: 2026/06/27
Narayana KamalLambert Isabel CBurford SamGosselin EmilieKörbelin JakobBrown Craig E